Financial Post |
- Aleafia Health Provides Update on the Negotiation of its Convertible Debt
- Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
- REPEAT — PowerTap Update on its Investee FusionOne, Producer of Hydrogen from Plastic Wastes
- Quipt Adds $13 Million in Annualized Revenue, $1.6 Million in Net Income, Anticipated $2.9 Million of Adjusted EBITDA Post Integration and 15,000 New Active Patients With Acquisition of Indiana Based Company
- Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries
- Avicanna Announces Changes to its Board of Directors
- Marathon Gold Announces Appointment of Chief Financial Officer
- Updated Credit Agreement Reached With TEC
- Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
- Titan Medical Completes Final Milestone Under Development Agreement with Medtronic
| Aleafia Health Provides Update on the Negotiation of its Convertible Debt Posted: 04 Jan 2022 04:35 AM PST The Company has initiated negotiations with debenture holders with a view of amending the Convertible Debt to achieve an outcome that is beneficial to all the Company's stakeholders. Read More |
| Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA Posted: 04 Jan 2022 04:35 AM PST CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306. The companies have a broad strategic collaboration to develop novel therapies to treat neurological disorders. BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy (SMA) that may have the potential to help address additional unmet needs of patients as well as to be administered at extended dosing intervals. Biogen plans to advance BIIB115 to clinical trials to investigate safety, tolerability, pharmacokinetics, and efficacy. Read More |
| REPEAT — PowerTap Update on its Investee FusionOne, Producer of Hydrogen from Plastic Wastes Posted: 04 Jan 2022 04:31 AM PST FusionOne is a producer of technologies primarily for the conversion of plastic waste to hydrogen and clean electricity with proprietary, patented pending technologies for the thermal processing of plastics and other carbon matter into clean "white" hydrogen and electricity. FusionOne has continued its efforts to commercialize its HydroPlas Reactor™️ with plastic polymer feedstocks and a number of other carbon-based waste feedstocks and is on track to have the first system operational in the first half of 2022, as planned and as announced in PowerTap's April 2021 announcement. Installation of the first reactor will be in feedstock rich Detroit, Michigan in the new year with final components arriving for full system commissioning in late February 2022. FusionOne has focused itself on securing its supply chain within North America and is pleased to have built strong relationships with key component suppliers able to meet FusionOne's growth plans over the coming years. Additional sites are expected to be announced in early 2022. Read More |
| Posted: 04 Jan 2022 04:31 AM PST CINCINNATI, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT; TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce that it has acquired At Home Health Equipment, Inc. ("At Home Health Equipment"), a business with operations in Indiana, reporting unaudited trailing 12-month annual revenues of approximately $13 million and $1.6 million in net income with anticipated Adjusted EBITDA (defined below) of $2.9 million (22% margin) post integration. As a reminder all figures stated are in USD. Read More |
| Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries Posted: 04 Jan 2022 04:31 AM PST SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Company's plans for developing R-107, the Company's nitric oxide-releasing compound, for multiple clinical indications. Read More |
| Avicanna Announces Changes to its Board of Directors Posted: 04 Jan 2022 04:30 AM PST TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the appointment of Eileen McCormack to, and the resignation of Setu Purohit from, its board of directors effective immediately. Read More |
| Marathon Gold Announces Appointment of Chief Financial Officer Posted: 04 Jan 2022 04:30 AM PST TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Marathon Gold Corporation ("Marathon" or the "Company"; TSX: MOZ) is pleased to report that Ms. Julie Robertson has been appointed Chief Financial Officer. Ms. Robertson's appointment will be effective March 7, 2022. Read More |
| Updated Credit Agreement Reached With TEC Posted: 04 Jan 2022 04:30 AM PST CALGARY, Alberta, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Pieridae Energy Limited ("Pieridae" or the "Company") (PEA.TO) today announced it has reached an agreement with its senior secured lender Third Eye Capital Corporation ("TEC") to extend payment of the $50 million term loan deferred fee (which was due January 4, 2022) and to amend certain other terms and covenants of the Credit Agreement first signed with TEC in October of 2019, related to the purchase of Shell's Foothills assets. Read More |
| Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference Posted: 04 Jan 2022 04:30 AM PST WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10 - 13, 2022. Read More |
| Titan Medical Completes Final Milestone Under Development Agreement with Medtronic Posted: 04 Jan 2022 04:30 AM PST TORONTO -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of innovative single access robotic-assisted surgery systems and technology, announced today that it completed, on schedule, the final milestone under the development and license agreement with Medtronic plc (NYSE: MDT), the world's leading medical technology company. With the successful completion of the agreement, Titan is scheduled to receive a license payment in exchange for licensing the developed technologies to Medtronic and Medtronic's secured loan to Titan will be retired, each of which are expected to be completed this month. Read More |
| You are subscribed to email updates from Financial Post. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment